Trials / Active Not Recruiting
Active Not RecruitingNCT04994795
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Deep Learning-Enabled Exploration of Predictive Signatures in a Multicenter Retrospective and Prospective Observational Study Allowing the Analysis of the Aggregation of Multimodal Clinical, Biological, Genomic and Radiomics Data Associated With the Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,000 (estimated)
- Sponsor
- Sophia Genetics SAS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Predictive models (data collection) | Machine learning predictive models |
Timeline
- Start date
- 2021-08-21
- Primary completion
- 2024-12-01
- Completion
- 2025-02-01
- First posted
- 2021-08-06
- Last updated
- 2024-11-21
Locations
30 sites across 8 countries: United States, Brazil, Canada, France, Germany, Israel, Italy, Spain
Source: ClinicalTrials.gov record NCT04994795. Inclusion in this directory is not an endorsement.